SyntekaBio,Inc.
Founded in 2009, SyntekaBio provides genomic big data-based AI drug discovery platforms DeepMatcher and NEO-ARS, along with the NGS-ARS precision medicine service.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2009 and listed on KOSDAQ in 2019, SyntekaBio is an AI drug discovery company built on genomic big data. It offers the AI drug discovery platform DeepMatcher (hit screening and lead optimization), NEO-ARS (neoantigen discovery), AB-ARS (antibody prediction and optimization), and the genomic precision medicine service NGS-ARS. NGS-ARS generates revenue through services provided to domestic university hospitals, and the company is developing its own drug pipeline (synthetic drugs, drug repositioning, neoantigen and antibody therapeutics) alongside a newly launched SI service that builds digital platforms for biotech companies.
Products & technology
- DeepMatcherHit screening and lead optimization service
- NEO-ARSPersonalized neoantigen discovery and screening service
- AB-ARSNovel antibody prediction and optimization service
- NGS-ARSGenomic precision medicine service, generating revenue from domestic university hospitals
- SI ServiceDigital platform (website/IR content) construction service for biotech companies
Regulatory approvals
data.go.kr2 Korean MFDS device approvals · 2020
- MFDSIVD reagents for extracting nucleic acids2020-03-20Product approval · Class 1체외 제신 20-377 호
- MFDSIVD reagents for extracting nucleic acids2020-02-10Product approval · Class 1체외 제신 20-168 호
R&D and key agreements
Source: DART corporate disclosure자체 신약파이프라인 · Synthetic drug, drug repositioning, and cancer vaccine/cell therapy target discovery using DeepMatcher and NEO-ARS
Companies approved for the same productsMedical AI
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.
Founded 2010, listed on KOSDAQ in 2021, Genesystem develops molecular diagnostic systems, biochips, test kits, and reaction reagents.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Founded in 1999 and listed on KONEX in 2017, Median Diagnostics develops and manufactures immunoassay, molecular, and point-of-care in vitro diagnostic kits for animal diseases.
Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.
KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition